13046_2018_1009_MOESM1_ESM.tif (1.03 MB)
Additional file 1: of Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer
figure
posted on 2019-01-23, 05:00 authored by Vivek Kashyap, Qinghui Wang, Saini Setua, Prashanth Nagesh, Neeraj Chauhan, Sonam Kumari, Pallabita Chowdhury, Duane Miller, Murali Yallapu, Wei Li, Meena Jaggi, Bilal Hafeez, Subhash ChauhanFigure S1. (A) Synthesis and chemical structure of VERU-111. (B) 1H NMR characterization of VERU-111 using CD2Cl2 as the NMR solvent and full assignment of proton chemical shifts of VERU-111 (EtOAC: ethyl acetate). Spectrum was acquired on a Bruker Advance III 400 MHz NMR spectrometer equipped with a BBO probe at room temperature. (TIF 1059 kb)
